Cryopep hemostasis coagulation - Deficient Human Plasma in Native VWF (VWD Type 3)

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (KITS)

Deficient Human Plasma in Native VWF (VWD Type 3)

Fresh frozen plasmas

Plasmas from patients with type 3 von Willebrand disease (VWD type 3) are fresh frozen plasmas obtained exclusively from donors with severe quantitative congenital von Willebrand factor (VWF) deficiency.

Reference	7-1403
Presentation	Kit
Format	5 x 1.0 mL
Quote

Price list, safety data sheets and notices are accessible to our registered customers.

Reference	Presentation	Format	Quote	Product sheet
7-1403	Kit	5 x 1.0 mL

Price list, safety data sheets and notices are accessible to our registered customers.

Willebrand's disease (VWD) is a genetic and hereditary disease which causes a qualitative or quantitative alteration of VWF causing more or less severe bleeding. VWDs are categorized into 3 types according to their faults :
Type 1 : the level of VWF is in lower quantity or having a shorter lifespan in the bloodstream, inducing a partial quantitative defect.
Type 2 : the level of VWF is in normal or slightly reduced quantity but it is altered in its structure inducing a qualitative deficit.
Type 3 : this is the most serious type because the VWF level is greatly reduced <1% of the normal associated with a decreased level of FVIII.

- This plasma is stable, if stored at -40 to -80 °C, until the end of the month of the expiration date indicated on the package.
- The stability of the product is 7 days at -20 °C.

- None of these plasmas contain inhibitors.
- No additives or preservatives.
- Freezing the plasmas makes it possible to keep the matrix perfectly intact and to avoid reconstitution.
-Packaging in plastic cryotubes suitable for all STA-R type micro-cup supports.

- 5 cryotubes x 1 mL of frozen plasma

Deficient Human Plasma in Native VWF (VWD Type 1)
Deficient Human Plasma in Native VWF (VWD Type 2B)

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (KITS)

Deficient Human Plasma in Native VWF (VWD Type 3)

Fresh frozen plasmas

Price list, safety data sheets and notices are accessible to our registered customers.

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep Catalogue
Thrombosis Haemostasis 2024

Cryopep Catalogue
Haemostasis Research 2024

Cryopep DEFICIENT PLASMAS

Product sheet Deficient Human Plasma in Native VWF (VWD Type 3)

CRYOPEP

You must identify yourself to search for a certificate of analysis

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (KITS)

Deficient Human Plasma in Native VWF (VWD Type 3)

Fresh frozen plasmas

Product sheet

Price list, safety data sheets and notices are accessible to our registered customers.

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep CatalogueThrombosis Haemostasis 2024

Cryopep CatalogueHaemostasis Research 2024

Cryopep DEFICIENT PLASMAS

Product sheet Deficient Human Plasma in Native VWF (VWD Type 3)

Cryopep Catalogue
Thrombosis Haemostasis 2024

Cryopep Catalogue
Haemostasis Research 2024